EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity

Megan Mendieta, Mehrdad Bandegi, Ezgi Biltekin, Yasemin M Akay iD, Bulent Ozpolat, Metin Akay iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26125533 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Megan Mendieta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering Department, University of Houston, Houston, TX 77204, USA. Hauptthemen laut MEDLINE: MicroRNAs, Temozolomide, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma Multiforme (GBM) is one of the most common brain tumors and is associated with aggressive tumor characteristics and extremely poor patient survival. The median survival time for GBM patients is around 12–15 months. Temozolomide (TMZ) is a key chemotherapeutic drug used in the treatment of GBM. However, at least 50% of GBM patients do not respond to TMZ, necessitating the identification of novel therapeutic strategies sensitizing patients to TMZ. In this study, we aimed to investigate the effects of two different tumor suppressor microRNAs (miR-329 and miR-449b) on cell proliferation and migration of GBM cells, and their potential for sensitizing GBM cells to TMZ. Our findings show that MiR-329/449b treatments suppressed spheroid formation and migration of GBM (LN229 and U87) cells. When miR treatments were combined with Temozolomide (TMZ), we also observed that they synergistically enhanced the suppressive effects of TMZ and inhibited the activity of clinically significant NF-KB and Src/FAK signaling pathways, making the combination therapy a viable option to treat GBM, with greater impact on patient survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsTemozolomideGlioblastomaBrain NeoplasmsHumansCell ProliferationCell MovementCell Line, TumorNF-kappa Bsrc-Family KinasesFocal Adhesion Kinase 1Cyclin D1Signal TransductionAntineoplastic Agents, AlkylatingGene Expression Regulation, NeoplasticDrug Synergism

Stichwörter der Autor:innen

GBMdrug resistancemiRNAmigrationsensitizationspheroidssynergy

Substanzen

MicroRNAsTemozolomideNF-kappa Bsrc-Family KinasesFocal Adhesion Kinase 1Cyclin D1PTK2 protein, humanAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Biomedical Engineering Department, University of Houston, Houston, TX 77204, USA.
  • Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.

ORCID-Profile: Yasemin M Akay, Metin Akay

Förderung

  • NIH HHS
  • NIH

Zitieren

APA

Mendieta, M., Bandegi, M., Biltekin, E., Akay, Y. M., Ozpolat, B., & Akay, M. (2025). MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26125533

Vancouver

Mendieta M, Bandegi M, Biltekin E, Akay YM, Ozpolat B, Akay M. MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26125533

BibTeX
@article{Mendieta2025,
  author = {Mendieta, Megan and Bandegi, Mehrdad and Biltekin, Ezgi and Akay, Yasemin M and Ozpolat, Bulent and Akay, Metin},
  title = {MiR 329/449 Suppresses Cell Proliferation, Migration and Synergistically Sensitizes GBM to TMZ by Inhibiting Src/FAK, NF-kB, and Cyclin D1 Activity},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26125533}
}
Kostenlos starten →